AMPHISTA THERAPEUTICS LIMITED

Amphista Therapeutics is a private biotechnology company headquartered in Cambridge, United Kingdom. The company is dedicated to the discovery and development of next-generation targeted protein degradation (TPD) medicines, with a mission to unlock the full potential of this therapeutic modality. Their core business involves selectively triggering the destruction and removal of specific pathogenic proteins associated with various diseases.

Amphista's key innovation lies in its proprietary Eclipsys™ platform and "Targeted Glues®" technology. These rationally designed molecules aim to overcome the limitations of first-generation TPD approaches by utilizing novel mechanisms that leverage a wider range of the body's innate protein degrading capabilities. The company's pipeline focuses on developing oral, brain-penetrant therapeutics across multiple disease areas, including oncology, neurodegenerative diseases, and immunology/inflammatory disorders. Notable programs include AMX-883, a BRD9 degrader for Acute Myeloid Leukaemia (AML), and SMARCA2 degraders for Non-Small Cell Lung Cancer (NSCLC).

In recent news, Amphista Therapeutics announced in March 2026 the appointment of Louise Modis as Chief Executive Officer and Patrick Kelly as Chief Medical Officer, strengthening its leadership as it prepares for clinical development. The company also presented new preclinical data for its SMARCA2 and TEAD Targeted Glue™ degrader programs, as well as the characterization of AMX-883, at the American Association for Cancer Research (AACR) Annual Meeting in April 2026. AMX-883 is expected to enter clinical trials in the second half of 2026. Amphista maintains strategic collaborations with pharmaceutical partners, including Bristol Myers Squibb, to advance its innovative TPD therapies.